Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology
Data from 1071 patients with acute decompensation reveals patterns that allow grouping patients into three different clinical courses with different mortality. The investigators have determined that the development of systemic inflammation is key to the progression of the disease and affects patients with pre-ACLF. Half of them die in three months and seven out of ten in 1 year. Read more.More news
MICROB-PREDICT Symposium connected to EASL School on Hepatology 2021 in Frankfurt
Management of acute-on-chronic liver failure - Course director: Prof. Jonel Trebicka - Location: Goethe University Frankfurt // Date: 01.07.2021More events